Testing a new immune therapy for advanced lung and neuroendocrine cancers

This trial is testing BI 764532 (also called obrixtamig), a new type of antibody-like medication designed to help your immune system fight advanced cancers. The study will test two different doses of the medication to find the right balance between effectiveness and safety. Researchers also want to see whether this treatment can shrink tumors in people with small cell lung cancer or other neuroendocrine cancers that have come back or stopped responding to previous treatments.

Small cell lung cancer and other neuroendocrine tumors are aggressive cancers that often return or resist standard chemotherapy and immunotherapy. This medication works in a new way by training your immune cells to recognize and attack cancer cells, offering hope for patients who have run out of other treatment options.